As we know, the lack of cellular immune response to tumor cells results from the poor presentation of antigens by DCs to CD8 + T cells and the inability of tumor vaccines to elicit sufficient DC activation to evoke the DC-derived co-stimulatory signals required to initiate effector CD8 + T-cell responses [63]. This evidence concerns the gene CD8A and neoplasm.